Scott Gettinger
0000-0003-0886-6880
Publication & Citation Trends
Publications
0 total
Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Cited by 0
Semantic Scholar
Abstract 7742: Intratumoral effector T-cells and macrophages underlie prolonged survival after PD-1 axis blockade in metastatic non-small cell lung cancer (mNSCLC)
Cited by 0
Semantic Scholar
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry OA
Cited by 17
Semantic Scholar
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Cited by 2
Semantic Scholar
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Cited by 17
Semantic Scholar
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Cited by 1
Semantic Scholar
Mesothelioma: Pleural, Version 1.2024. OA
Cited by 25
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(388)
Cancer Immunotherapy and Biomarkers
(303)
Lung Cancer Research Studies
(129)
Cancer Genomics and Diagnostics
(96)
Colorectal Cancer Treatments and Studies
(90)
Affiliations
University of North Carolina at Chapel Hill
Christiana Care Health System
Cedars-Sinai Medical Center
Mount Sinai Beth Israel
Memorial Hospital of South Bend